

# Josã Leal

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1375073/publications.pdf>

Version: 2024-02-01

84  
papers

5,389  
citations

136740

32  
h-index

85405

71  
g-index

86  
all docs

86  
docs citations

86  
times ranked

8753  
citing authors

#	ARTICLE	IF	CITATIONS
1	Costs of Joint Replacement in Osteoarthritis: A Study Using the National Joint Registry and Clinical Practice Research Datalink Data Sets. <i>Arthritis Care and Research</i> , 2022, 74, 392-402.	1.5	11
2	An Intuitive Risk Communication Tool to Enhance Patient-Provider Partnership in Diabetes Consultation. <i>Journal of Diabetes Science and Technology</i> , 2022, 16, 988-994.	1.3	1
3	Appraisal of patient-level health economic models of severe mental illness: systematic review. <i>British Journal of Psychiatry</i> , 2022, 220, 86-97.	1.7	3
4	Performance of the UK Prospective Diabetes Study Outcomes Model 2 in a Contemporary UK Type 2 Diabetes Trial Cohort. <i>Value in Health</i> , 2022, 25, 435-442.	0.1	4
5	Lifetime cost-effectiveness simulation of once-weekly exenatide in type 2 diabetes: A cost-utility analysis based on the EXSCEL trial. <i>Diabetes Research and Clinical Practice</i> , 2022, 183, 109152.	1.1	2
6	Cost-effectiveness of home-based stroke rehabilitation across Europe: A modelling study. <i>Health Policy</i> , 2022, 126, 183-189.	1.4	9
7	Health-related quality of life for normal glycaemia, prediabetes and type 2 diabetes mellitus: Cross-sectional analysis of the ADDITION-PRO study. <i>Diabetic Medicine</i> , 2022, 39, e14825.	1.2	5
8	Efficacy of Liposomal Bupivacaine and Bupivacaine Hydrochloride vs Bupivacaine Hydrochloride Alone as a Periarticular Anesthetic for Patients Undergoing Knee Replacement. <i>JAMA Surgery</i> , 2022, 157, 481.	2.2	12
9	Decrement in health-related quality of life associated with adverse events in people with diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 530-538.	2.2	9
10	Exploring Structural Uncertainty and Impact of Health State Utility Values on Lifetime Outcomes in Diabetes Economic Simulation Models: Findings from the Ninth Mount Hood Diabetes Quality-of-Life Challenge. <i>Medical Decision Making</i> , 2022, 42, 599-611.	1.2	5
11	The transferability and validity of a population-level simulation model for the economic evaluation of interventions in diabetes: the MICADO model. <i>Acta Diabetologica</i> , 2022, 59, 949-957.	1.2	2
12	Hospital costs associated with adverse events in people with diabetes in the UK. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 2108-2117.	2.2	5
13	Prediction of mortality and major cardiovascular complications in type 2 diabetes: External validation of UK Prospective Diabetes Study outcomes model version 2 in two European observational cohorts. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1084-1091.	2.2	8
14	Cost-Effectiveness of Mechanical Thrombectomy for Treatment of Nonminor Ischemic Stroke Across Europe. <i>Stroke</i> , 2021, 52, 664-673.	1.0	16
15	Estimating risk factor progression equations for the UKPDS Outcomes Model 2 (UKPDS 90). <i>Diabetic Medicine</i> , 2021, 38, e14656.	1.2	10
16	Home-based rehabilitation programme compared with traditional physiotherapy for patients at risk of poor outcome after knee arthroplasty: the CORKA randomised controlled trial. <i>BMJ Open</i> , 2021, 11, e052598.	0.8	11
17	Physiotherapy rehabilitation for osteoporotic vertebral fracture—a randomised controlled trial and economic evaluation (PROVE trial). <i>Osteoporosis International</i> , 2020, 31, 277-289.	1.3	19
18	Economic burden of stroke across Europe: A population-based cost analysis. <i>European Stroke Journal</i> , 2020, 5, 17-25.	2.7	139

#	ARTICLE	IF	CITATIONS
19	Within-Trial Evaluation of Medical Resources, Costs, and Quality of Life Among Patients With Type 2 Diabetes Participating in the Exenatide Study of Cardiovascular Event Lowering (EXSCCEL). <i>Diabetes Care</i> , 2020, 43, 374-381.	4.3	4
20	Health-related quality of life in people with predementia Alzheimer's disease, mild cognitive impairment or dementia measured with preference-based instruments: a systematic literature review. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 154.	3.0	37
21	Evaluating the Ability of Economic Models of Diabetes to Simulate New Cardiovascular Outcomes Trials: A Report on the Ninth Mount Hood Diabetes Challenge. <i>Value in Health</i> , 2020, 23, 1163-1170.	0.1	32
22	Benchmarking the Cost-Effectiveness of Interventions Delaying Diabetes: A Simulation Study Based on NAVIGATOR Data. <i>Diabetes Care</i> , 2020, 43, 2485-2492.	4.3	3
23	Accurately Reflecting Uncertainty When Using Patient-Level Simulation Models to Extrapolate Clinical Trial Data. <i>Medical Decision Making</i> , 2020, 40, 460-473.	1.2	15
24	Comparison of the clinical and cost effectiveness of two management strategies (rehabilitation) protocol for the ACL SNNAP randomised controlled trial. <i>Trials</i> , 2020, 21, 405.	0.7	20
25	Enhanced recovery following hip and knee arthroplasty: a systematic review of cost-effectiveness evidence. <i>BMJ Open</i> , 2020, 10, e032204.	0.8	14
26	The impact of the enhanced recovery pathway and other factors on outcomes and costs following hip and knee replacement: routine data study. <i>Health Services and Delivery Research</i> , 2020, 8, 1-188.	1.4	5
27	Total versus partial knee replacement in patients with medial compartment knee osteoarthritis: the TOPKAT RCT. <i>Health Technology Assessment</i> , 2020, 24, 1-98.	1.3	27
28	Outpatient physiotherapy versus home-based rehabilitation for patients at risk of poor outcomes after knee arthroplasty: CORKA RCT. <i>Health Technology Assessment</i> , 2020, 24, 1-116.	1.3	62
29	The clinical and cost-effectiveness of total versus partial knee replacement in patients with medial compartment osteoarthritis (TOPKAT): 5-year outcomes of a randomised controlled trial. <i>Lancet</i> , 2019, 394, 746-756.	6.3	195
30	The Challenge of Transparency and Validation in Health Economic Decision Modelling: A View from Mount Hood. <i>Pharmacoeconomics</i> , 2019, 37, 1305-1312.	1.7	28
31	Impact of achieving primary care targets in type 2 diabetes on health outcomes and healthcare costs. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2405-2412.	2.2	10
32	Geographical Variation in Outcomes of Primary Hip and Knee Replacement. <i>JAMA Network Open</i> , 2019, 2, e1914325.	2.8	22
33	Impact of a national enhanced recovery after surgery programme on patient outcomes of primary total knee replacement: an interrupted time series analysis from The National Joint Registry of England, Wales, Northern Ireland and the Isle of Man. <i>Osteoarthritis and Cartilage</i> , 2019, 27, 1280-1293.	0.6	20
34	Decision models of prediabetes populations: A systematic review. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1558-1569.	2.2	21
35	Automated virtual reality (VR) cognitive therapy for patients with psychosis: study protocol for a single-blind parallel group randomised controlled trial (gameChange). <i>BMJ Open</i> , 2019, 9, e031606.	0.8	36
36	Assessment on patient outcomes of primary hip replacement: an interrupted time series analysis from The National Joint Registry of England and Wales. <i>BMJ Open</i> , 2019, 9, e031599.	0.8	4

#	ARTICLE	IF	CITATIONS
37	Study of Peri-Articular Anaesthetic for Replacement of the Knee (SPAARK): study protocol for a patient-blinded, randomised controlled superiority trial of liposomal bupivacaine. <i>Trials</i> , 2019, 20, 732.	0.7	2
38	Cost-effectiveness of digital surveillance clinics with optical coherence tomography versus hospital eye service follow-up for patients with screen-positive maculopathy. <i>Eye</i> , 2019, 33, 640-647.	1.1	25
39	Delayed Hospital Discharges of Older Patients: A Systematic Review on Prevalence and Costs. <i>Gerontologist</i> , The, 2019, 59, e86-e97.	2.3	52
40	Exercise or manual physiotherapy compared with a single session of physiotherapy for osteoporotic vertebral fracture: three-arm PROVE RCT. <i>Health Technology Assessment</i> , 2019, 23, 1-318.	1.3	13
41	Estimating the sensitivity of a prostate cancer screening programme for different PSA cut-off levels: A UK case study. <i>Cancer Epidemiology</i> , 2018, 52, 99-105.	0.8	8
42	Computer Modeling of Diabetes and Its Transparency: A Report on the Eighth Mount Hood Challenge. <i>Value in Health</i> , 2018, 21, 724-731.	0.1	63
43	Longitudinal medical resources and costs among type 2 diabetes patients participating in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1732-1739.	2.2	5
44	Cost-effectiveness of enhanced recovery in hip and knee replacement: a systematic review protocol. <i>BMJ Open</i> , 2018, 8, e019740.	0.8	10
45	Healthcare and wider societal implications of stillbirth: a population-based cost-of-illness study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2018, 125, 108-117.	1.1	29
46	The Impact of Hospital Costing Methods on Cost-Effectiveness Analysis: A Case Study. <i>Pharmacoeconomics</i> , 2018, 36, 1263-1272.	1.7	14
47	Risk attitudes of people with "manageable"™ chronic disease: An analysis under prospect theory. <i>Social Science and Medicine</i> , 2018, 214, 144-153.	1.8	24
48	Cost-effectiveness of a pragmatic structured education intervention for the prevention of type 2 diabetes: economic evaluation of data from the Let's Prevent Diabetes cluster-randomised controlled trial. <i>BMJ Open</i> , 2017, 7, e013592.	0.8	22
49	Process mining routinely collected electronic health records to define real-life clinical pathways during chemotherapy. <i>International Journal of Medical Informatics</i> , 2017, 103, 32-41.	1.6	69
50	Computer simulation models of pre-diabetes populations: a systematic review protocol. <i>BMJ Open</i> , 2017, 7, e014954.	0.8	4
51	Reducing social isolation and loneliness in older people: a systematic review protocol. <i>BMJ Open</i> , 2017, 7, e013778.	0.8	130
52	General hospital costs in England of medical and psychiatric care for patients who self-harm: a retrospective analysis. <i>Lancet Psychiatry</i> , the, 2017, 4, 759-767.	3.7	78
53	Costs of fragility hip fractures globally: a systematic review and meta-regression analysis. <i>Osteoporosis International</i> , 2017, 28, 2791-2800.	1.3	152
54	Perceptions of risks for diabetes-related complications in Type 2 diabetes populations: a systematic review. <i>Diabetic Medicine</i> , 2017, 34, 467-477.	1.2	41

#	ARTICLE	IF	CITATIONS
55	Cost-Effectiveness of Orthogeriatric and Fracture Liaison Service Models of Care for Hip Fracture Patients: A Population-Based Study. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 203-211.	3.1	62
56	A community-based primary prevention programme for type 2 diabetes mellitus integrating identification and lifestyle intervention for prevention: a cluster randomised controlled trial. <i>Programme Grants for Applied Research</i> , 2017, 5, 1-290.	0.4	12
57	Economic impact of early intervention in psychosis services: results from a longitudinal retrospective controlled study in England. <i>BMJ Open</i> , 2016, 6, e012611.	0.8	45
58	Economic Burden of Bladder Cancer Across the European Union. <i>European Urology</i> , 2016, 69, 438-447.	0.9	223
59	Anti-Osteoporosis Medication Prescriptions and Incidence of Subsequent Fracture Among Primary Hip Fracture Patients in England and Wales: An Interrupted Time-Series Analysis. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 2008-2015.	3.1	61
60	Economic burden of non-malignant blood disorders across Europe: a population-based cost study. <i>Lancet Haematology</i> , 2016, 3, e371-e378.	2.2	15
61	Economic burden of malignant blood disorders across Europe: a population-based cost analysis. <i>Lancet Haematology</i> , 2016, 3, e362-e370.	2.2	25
62	Impact of hip fracture on hospital care costs: a population-based study. <i>Osteoporosis International</i> , 2016, 27, 549-558.	1.3	249
63	The impact of social isolation on delayed hospital discharges of older hip fracture patients and associated costs. <i>Osteoporosis International</i> , 2016, 27, 737-745.	1.3	56
64	UK research spend in 2008 and 2012: comparing stroke, cancer, coronary heart disease and dementia. <i>BMJ Open</i> , 2015, 5, e006648-e006648.	0.8	56
65	The impact of diabetes-related complications on healthcare costs: new results from the UKPDS (UKPDS) Tj ETQq1, 1, 0.784314 rgBT 160	1.2	160
66	Development of a cost-effectiveness model for optimisation of the screening interval in diabetic retinopathy screening. <i>Health Technology Assessment</i> , 2015, 19, 1-116.	1.3	90
67	Estimating age and ethnic variation in the histological prevalence of prostate cancer to inform the impact of screening policies. <i>International Journal of Urology</i> , 2014, 21, 786-792.	0.5	11
68	Regional differences in the frequency of the c. 985A >G ACADM mutation: findings from a meta-regression of genotyping and screening studies. <i>Clinical Genetics</i> , 2014, 85, 253-259.	1.0	10
69	Performance of the UKPDS Outcomes Model for Prediction of Myocardial Infarction and Stroke in the ADDITION-Europe Trial Cohort: Does the ADDITION Validation Add Up?. <i>Value in Health</i> , 2014, 17, 895-896.	0.1	1
70	Epidemiology of fragile X syndrome: A systematic review and meta-analysis. <i>American Journal of Medical Genetics, Part A</i> , 2014, 164, 1648-1658.	0.7	320
71	Synthesis framework estimating prevalence of MCADD and sensitivity of newborn screening programme in the absence of direct evidence. <i>Journal of Clinical Epidemiology</i> , 2014, 67, 1131-1138.	2.4	2
72	UKPDS Outcomes Model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30-year United Kingdom Prospective Diabetes Study: UKPDS 82. <i>Diabetologia</i> , 2013, 56, 1925-1933.	2.9	315

#	ARTICLE	IF	CITATIONS
73	Temporal Validation of the UKPDS Outcomes Model Using 10-Year Posttrial Monitoring Data. <i>Diabetes Care</i> , 2013, 36, 1541-1546.	4.3	21
74	Economic burden of cancer across the European Union: a population-based cost analysis. <i>Lancet Oncology</i> , The, 2013, 14, 1165-1174.	5.1	718
75	UK research expenditure on dementia, heart disease, stroke and cancer: are levels of spending related to disease burden?. <i>European Journal of Neurology</i> , 2012, 19, 149-154.	1.7	65
76	Cost of Dementia in the Pre-Enlargement Countries of the European Union. <i>Journal of Alzheimer's Disease</i> , 2011, 27, 187-196.	1.2	57
77	Risk equations to predict life expectancy of people with Type 2 diabetes mellitus following major complications: a study from Western Australia. <i>Diabetic Medicine</i> , 2011, 28, 428-435.	1.2	21
78	DNA testing for hypertrophic cardiomyopathy: a cost-effectiveness model. <i>European Heart Journal</i> , 2010, 31, 926-935.	1.0	140
79	Development of life-expectancy tables for people with type 2 diabetes. <i>European Heart Journal</i> , 2009, 30, 834-839.	1.0	112
80	Bridging science and health policy in cardiovascular disease: focus on lipid management. <i>Atherosclerosis Supplements</i> , 2009, 10, 3-21.	1.2	10
81	Estimating the Cost of Complications of Diabetes in Australia Using Administrative Health-Care Data. <i>Value in Health</i> , 2008, 11, 199-206.	0.1	68
82	Eliciting Expert Opinion for Economic Models: An Applied Example. <i>Value in Health</i> , 2007, 10, 195-203.	0.1	57
83	Economic burden of cardiovascular diseases in the enlarged European Union. <i>European Heart Journal</i> , 2006, 27, 1610-1619.	1.0	571
84	Cost of cardiovascular diseases in the United Kingdom. <i>Heart</i> , 2006, 92, 1384-1389.	1.2	154